Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. has seen a significant increase in its probability of success assumptions for the FDA approval of its drug bitopertin, now assessed at 100%, which reflects a high confidence in its potential market entry and revenue generation. The company has a diverse clinical pipeline, with estimated sales poised to increase substantially from $35 million in 2026 to $615 million by 2029, indicating strong future growth prospects driven by its various therapeutic candidates. Additionally, the receipt of a Commissioner’s National Priority Voucher for bitopertin is set to expedite its drug application review time, further enhancing the company's strategic position and potential for accelerated revenue realization.

Bears say

Disc Medicine Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include potential erosion of pricing power due to competition and regulatory changes, a fragile intellectual property position that may hamper revenue expectations, and a significant financing risk that necessitates raising capital before reaching profitability. Additionally, the company’s drug candidates, particularly bitopertin and DISC-0974, may fail to demonstrate adequate efficacy or safety in clinical trials, while limited cash reserves further exacerbate the challenges associated with advancing its development pipeline.

IRON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 10 analysts, IRON has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.